United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $560.07, for a total value of $5,320,665.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares of the company’s stock, valued at approximately $181,710,791.01. The trade was a 2.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

United Therapeutics Stock Performance

Shares of UTHR stock traded up $21.30 during trading hours on Thursday, reaching $584.79. The company had a trading volume of 878,421 shares, compared to its average volume of 556,722. The business has a fifty day moving average price of $515.71 and a 200-day moving average price of $539.59. United Therapeutics Corporation has a one year low of $409.07 and a one year high of $609.35. The firm has a market cap of $25.08 billion, a PE ratio of 20.92, a price-to-earnings-growth ratio of 3.96 and a beta of 0.49.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, beating analysts’ consensus estimates of $6.86 by $0.41. The company had revenue of $783.30 million for the quarter, compared to the consensus estimate of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%. United Therapeutics’s revenue was down 1.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $6.41 earnings per share. Equities research analysts forecast that United Therapeutics Corporation will post 26.40 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on UTHR. Morgan Stanley raised their price objective on United Therapeutics from $515.00 to $566.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 7th. Leerink Partners lifted their price objective on shares of United Therapeutics from $685.00 to $725.00 and gave the stock an “outperform” rating in a research note on Monday. Raymond James Financial reiterated an “outperform” rating and set a $717.00 price objective on shares of United Therapeutics in a research report on Tuesday. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, August 27th. Finally, The Goldman Sachs Group reissued a “sell” rating and issued a $368.00 target price on shares of United Therapeutics in a research note on Thursday, October 15th. Twelve equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $650.43.

Institutional Trading of United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in UTHR. Toth Financial Advisory Corp boosted its stake in shares of United Therapeutics by 2,400.0% during the second quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 48 shares in the last quarter. Fiduciary Financial Advisors purchased a new position in United Therapeutics during the second quarter valued at approximately $30,000. Caitlin John LLC bought a new position in United Therapeutics in the second quarter worth approximately $37,000. International Assets Investment Management LLC raised its stake in United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock worth $45,000 after buying an additional 64 shares in the last quarter. Finally, PFS Partners LLC bought a new position in United Therapeutics in the third quarter worth approximately $45,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for patients with life-threatening conditions, particularly pulmonary arterial hypertension (PAH). The company’s portfolio includes Tyvaso and Tyvaso DPI, inhaled formulations of treprostinil; Remodulin, an injectable treprostinil product; and Orenitram, an oral treprostinil therapy. These treatments are designed to improve exercise ability and delay disease progression in people with PAH.

The company also markets Unituxin, an antibody therapy used as part of treatment for high-risk neuroblastoma, a type of childhood cancer.